FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 12/2024 published

 

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 12/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of December 2024 we identified the following current VC trends in the United States:

 

  • In 2024 total Healthcare & Life Sciences VC-funding volume reached EUR 34,864m. This represents an increase of 11% vs. 2023 funding volume (EUR 31,398m)
  • Biotech & Pharma received 52% of the total investment volume (EUR 18,201m) with oncology being the leading indication (28%)
  • In contrast to increased funding volume in 2024 the total number of VC-Deals declined by 8,6% vs. prior year (1,570 VC-Deals in 2024 vs. 1,719 VC-Deals in 2023)
  • Therefore, on average 2024 saw a smaller number of VC-Deals but with larger ticket sizes (2024 average ticket size of EUR 22.2m vs. 2023 average ticket size of EUR 18.3m)
  • In 2024 RA Capital Management (United States) was the most active investor (by deal volume), followed by ARCH Venture Partners (United States) and Atlas Venture (United States)
  • In December Nuvig Therapeutics secured the highest transaction volume with EUR 152m, followed by Patho Care with EUR 143m and Boston Gene with EUR 113m

 

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link